June 19th 2025
The drug could also reduce chronic kidney disease when combined with insulin therapy.
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
PBM Challenges and the Evolving Role of Oncology Pharmacists in Community Practices
0.75 Credit / Oncology, Law
View More
FDA Clears First Prescription Game-Based Treatment Device for Children With ADHD
June 17th 2020EndeavorRx (Akili Interactive), a prescription-only game-based device, is indicated for use in children ages 8 to 12 years old with primarily inattentive or combined-type ADHD who have demonstrated an attention issue.
Psychotropic Drugs in Pediatrics: Looking at the Whole Child
December 21st 2018Each year, approximately 200,000 children ages 17 years and younger land in emergency departments (EDs) from adverse drug events (ADEs). Children younger than 5 years of age are most likely to visit the ED for ADEs, according to the CDC.
APP Pharmaceuticals releasing more preservative-free methotrexate
March 15th 2012Continuing to work with FDA to ease the ongoing shortage of injectable methotrexate, APP Pharmaceuticals this week released another 10,000 vials of preservative-free methotrexate (Methotrexate Injection), a drug used in the treatment of pediatric oncology and hematology
First synthetic, peptide-containing surfactant for prevention of RDS approved
March 8th 2012FDA has approved lucinactant (Surfaxin, Discovery Labs) for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. Surfaxin is the first synthetic, peptide-containing surfactant approved for use in neonatal medicine.